A new study published in Journal of Experimental Psychology: Applied examines the impact of racial bias in the way children’s pain is perceived by clinicians. Unfortunately, this study confirms that racial bias continues to contribute to inequities in managing pain among racialized children. According to the paper: “This work finds that adult perceivers believed Black […]
QUESTION OF THE MONTH/VISUAL PEARLS/POLLS OF THE MONTH
SEPTEMBER 2023 POLL OF THE MONTH
SEPTEMBER 2023 QUESTION OF THE MONTH
A 16-year-old female with chronic migraine without aura comes to your clinic with her mother. She is having 2-3 migraines a week, but her mother notes she has milder headaches a couple of days a week as well. She is missing school frequently and has stopped participating in band. The patient has tried cyproheptadine and amitriptyline as preventive medications with naproxen as an abortive medication. She has not seen a decrease in the number of her monthly headaches, and the naproxen has been helpful, but it does not relieve the migraine. They received a few samples of rimegepant from their PCP, but their insurance company is not going to cover it. Despite her willingness to try off-label medications prior, now her mother is only interested in trying treatments that are FDA approved for pediatrics.
Which of the following preventive and abortive treatment combinations should you consider for this adolescent?
A.) OnabotulinumtoxinA injections and eletriptan
B.) Topiramate and almotriptan
C.) Fremanezumab and sumatriptan
D.) Amitriptyline and rizatriptan